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SUPPLEMENTARY METHODS
Calculation of chemical and protein descriptors. Chemical descriptors were calculated using the DRAGONX program (version 1.2; Talete S.r.l., Milan, Italy). In this study, 929 descriptors were calculated from descriptor categories 1-10 (constitutional descriptors, topological descriptors, walk and path counts, connectivity indices, information indices, twodimensional (2D) autocorrelations, edge-adjacency indices, Burden eigenvalue descriptors, topological charge indices and eigenvalue-based indices), categories 17 and 18 (functional group counts and atom-centered fragments), and category 20 (molecular properties). Note that descriptors with values dependent on the 3D coordinates of the molecules (descriptor categories 11-14) were not used. Additionally, descriptors that count functional groups and atom types (categories 15 and 16) were omitted due to output errors of the program. Also, charge descriptors (category 19) were omitted because their values depend on the condition of the molecules. Finally, descriptors showing little variation across the compounds were eliminated. As a result, 797 descriptors were used for the subsequent processing.
Protein descriptors were calculated from the sequences alone. Specifically, dipeptide composition-based description (a mismatch-allowed spectrum kernel) was used to represent GPCRs, providing 400 dimensions. Mismatch-allowed spectrum kernel is based on shared occurrences of (k,m) patterns in the protein sequence, where the (k,m) pattern generated by a fixed k-length sub-sequence consists of all k-length sub-sequences differing from it by, at most, m mismatches. We set (k,m) at (2,1); hence, the number of descriptors is 20 2 (=400) (Leslie et al., 2004) . These descriptors are simple, yet are known to be quite good at predicting protein structural classes, functional classes, and subcellular localizations (Bhasin and Raghava, 2004; Hua and Sun, 2001 ). The advantage of using such descriptors lies in their being alignment-free and the easy to handle varying sequence lengths. After completing the series of experiments on GPCRs, we found that using additional descriptors, such as sequence-derived physicochemical features together with dipeptide composition, could lead to even better prediction models. In view of this observation, we chose to use a set of descriptors consisting of 1,497 features provided by the PROFEAT Webserver (Li et al., 2006) in the next series of experiments on kinases. Additionally, calculation of these descriptors was applied not to full-length sequences, but to domain sequences, because the five-fold cross validations confirmed that the domain sequence-based descriptor exhibited better accuracy (89.76%) than the full-length based descriptor (88.08%), consistent with the fact that kinase active sites tend to be localized in their domain sequences.
Construction of the prediction model using SVM. The SVM represents a class of statistical learning algorithms, the theoretical basis of which was first given by Vapnik (Vapnik, 1995) .
Due to its high generalization ability, the SVM has been applied to pattern recognition problems in various areas. A SVM classifier constructs a hyperplane that separates two different groups with a maximum margin, which is defined as the closest distance from any point to the separating hyperplane.
To find an optimal hyperplane that discriminates the presence and absence of CPIs, we constructed numerical vectors for compound-protein pairs (both for positive and negative samples) by concatenating chemical descriptors and protein descriptors, which were input to the SVM for learning. As information about non-interaction pairs was unavailable, we randomly generated the same number of negative samples as that of positive samples from pairs with unknown interactions. We used a portion of the codes from the LIBSVM suite of programs (http://www.csie.ntu.edu.tw/~cjlin/libsvm), which employs a modified version of the sequential minimal optimization (SMO) algorithm (Schölkopf et al., 2004; Platt, 1999) .
The parameters of the SVM with the radial basis function (RBF) kernel were optimized by a grid search.
Once the SVM classifier was obtained, we could test whether other CPIs have interactions. In addition to a simple output of a yes/no decision, scores could be assigned to the samples by estimating the SVM confidence in the correctness of the predicted outputs (Platt, 2000) . This scoring method is based on the idea that samples lying closer to the hyperplane have a larger probability of being misclassified than those lying far away. We ranked all the tested CPIs according to the probability scores.
LBVS methods based on chemical similarity. We used popular ligand-based screening methods that compute the similarity of chemical descriptors. The neighboring compounds in the space defined by the chemical descriptors tend to show similar properties and biological activities; thus, these methods can be used to help in the discovery of lead compounds (Oprea, 2002) . We scored the chemical compounds according to the distance to known ligands in the principal component (PC) space (Jolliffe, 1986) of the chemical descriptors. The number of PCs was determined so that the cumulative proportion of the explained variance exceeded 80%. We scored a pair of compound A and protein B on the basis of the similarity between compound A and the known ligands of protein B. Specifically, Pearson correlation coefficients were calculated between compound A and all known ligands of protein B in the PC space, and the maximum (that is, the similarity to the nearest-neighbor known ligand) was chosen as the score. We call this method the nearest neighbor (NN) with principal components analysis (NN-PCA). We also applied NN with the Tanimoto coefficient (NN-TC) and NN with the Pearson correlation coefficient (NN-PCC) in the original space.
Five-fold CV for the CGBVS and LBVS methods. The prediction performance was evaluated by five-fold CV, whereby samples were randomly split into five subsets of almost equal size; a classifier was constructed using four subsets (training set) and tested on the remaining subset (test set), and this process was repeated five times. The parameters of each classifier were optimized using a grid search with nested cross-validation, i.e., the abovementioned training set was further split into three subsets (training set) and one subset (test set), and the best parameters were selected through the four-fold CVs.
Performance measures (shown in Supplementary Table S2) and false-negatives, respectively. We also used the ROC curve (Hanley and McNeil, 1982) , which shows the false-positive rate versus the true-positive rate: that is, 1 -specificity versus sensitivity. The threshold was chosen as the farthest point from the diagonal line indicating a random ROC. Taking into account the performance variation caused particularly by the random generation of negative samples, we repeated the five-fold CV 20 times with different positive and negative sample sets. Our proposed CGBVS was compared to the other methods in terms of the mean accuracy of the five-fold CV, and the ROC curve.
Polypharmacological prediction for ADRB2. We predicted the probability of interaction of 826 compounds (excluding the 40 known ADRB2 ligands) with ADRB2 using a prediction model of CGBVS, which was constructed for validation with ADRB2 functional assays. Then, we ranked the compounds according to the CGBVS scores and carried out further analysis for the 50 top-ranked compounds. First, we surveyed the literature about the interaction between ADRB2 and these compounds using SciFinder (Wagner, 2006) . After a 1 h incubation at 37°C, unbound and membrane-bound radioactivity were separated by filtration of the samples through a glass fiber filter, followed by 10 washing steps with 200 μL ice-cold binding buffer, and were measured by liquid scintillation counting. Nonspecific binding was determined in the presence of 0.1 μM unlabelled propranolol. Here, we decided the ligand with K i < 100 μM as active.
Comprehensive predictions of binding modes between proteins and their ligands. As well as the prospective screening for ADRB2, we applied CGBVS to all the remaining compound-protein pairs. The prediction scores for all of the combinations between the proteins and their ligands were displayed as a 2D color map. Then, the number of predicted common ligands between every pair of proteins was represented by the elements of a polypharmacological interaction matrix in Figure 3C .
Analysis of ligand promiscuity. We used extended-connectivity fingerprints (ECFP_6) as implemented by Pipeline Pilot (version 6.1.5; Accelrys, San Diego) to represent chemical substructures. The propensity for ligand promiscuity was defined as the posterior probability of promiscuity against selectivity given a substructure. The probability was calculated for each substructure using the Laplacian-corrected estimator (Xia et al., 2004) . The substructures with high probabilities were considered characteristic of the promiscuous ligands. μL of Termination Buffer (QuickScout Screening Assist MSA; Carna Biosciences, Kobe, Japan) was added to each well. The reaction mixture was applied to a LabChip3000 system (Caliper Life Sciences, Hopkinton, MA), and the product and substrate peptide peaks were separated and quantitated. The kinase reaction was evaluated by the product ratio calculated from peak heights of product (P) and substrate (S) peptides [P/(P + S)]. Primary screening was performed using 50 μM of test compound. Then, potent compounds showing more than 20% inhibition were selected for secondary screening to determine IC 50 values.
Assessment of the novelty of the compound bioactivity. We carefully performed a literature search for all hit compounds to confirm the novelty of their bioactivities. First, a chemical structure search was carried out using SciFinder and PubChem. If an identical structure was found, we looked for references to the compound in biological experiments. Finally, we classified the bioactivity of the compound into two cases; one was the case of no report for our assayed target (i.e., ADRB2, NPY1R, EGFR, or CDK2), though bioactivities for other targets were reported, and the other was the case of no report about any biological activities.
Consequently, in the ADRB2 ligands, compound 8 (1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]-2-propanol) was previously reported to antagonize ADRB2 activity.
has been found to show agonistic/antagonistic activities on other GPCRs such as serotonin (Supplementary Tables S5, S8 , S13, S14 and S15), and chemical structure images for trained/predicted compounds are available at http://pharminfo.pharm.kyoto-u.ac.jp/services/glida/cgbvs/ . BLAST (Altschul et al., 1990 ). An enlarged map is available at http://pharminfo.pharm.kyoto-u.ac.jp/services/glida/cgbvs/cpimap.php?fam=orphan. 
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